For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- OPMA to Develop Projects for Kansai Innovation Special area
October 11, 2011
- JACDS to Propose Reforms to Promote Switch-OTC Progress in Japan
October 11, 2011
- Association-managed Pharmacies Should Become “Home Healthcare Support Centers”: Mr Kodama of JPA
October 11, 2011
- JPA Announces FY2010 Results of Drug Event Monitoring for SU Drugs
October 11, 2011
- JPMA to Work with IFPMA to Tackle Non-communicable Diseases in Developing World
October 10, 2011
- Speed, Quality of Clinical Trials Have Increased: Mr Kawaguchi of JPMA
October 10, 2011
- Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
- Permanent Introduction of Premium for New Drug Development Is an Option: Executive Director Miura of JPA
October 3, 2011
- Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
- “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
- JPA, JSHP Announce Glossary of Standard Terminology for Drug Prescriptions
September 30, 2011
- No Correlation Between Drowsiness and Efficacy of 2nd-Generation Antihistamine Drugs: HIRS
September 30, 2011
- JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
- JPMA Asks for Continued R&D Tax Credit System
September 26, 2011
- Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
- FY2010 Deficit 2nd-Biggest Ever: Kenporen
September 26, 2011
- Over 95% of Patients Agree to Investigational Use of Removed Tissues: NCC Chief Director Kayama
September 22, 2011
- FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
- Discontinue Re-pricing Following Market Expansion: Mr Umeda of PhRMA
September 19, 2011
- NIBIO Project Making Progress in Discovery of Safety Biomarkers for Evaluating Drug Toxicity
September 19, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…